查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916197

光学成像剂市场按产品类型、成像方式、应用和最终用户划分－2026-2032年全球预测

Optical Imaging Agent Market by Product Type, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，光学成像剂市场价值将达到 24.5 亿美元，到 2026 年将成长至 25.7 亿美元，到 2032 年将达到 38.5 亿美元，年复合成长率为 6.66%。

关键市场统计数据
基准年 2025 24.5亿美元
预计年份：2026年 25.7亿美元
预测年份 2032 38.5亿美元
复合年增长率 (%) 6.66%

光学成像剂的全面介绍：重点关注技术整合、临床应用压力和策略发展需求

光学影像剂领域融合了前沿化学、分子生物学和临床诊断技术，目前正吸引临床医生、研究人员和相关人员的关注，他们寻求的是更高对比、更特异性、更安全的影像解决方案。探针设计、影像仪器和多模态整合技术的进步，正将光学工具的临床效用从实验室拓展到术中导航、标靶诊断和非侵入性疾病监测等领域。同时，监管路径和报销机制也不断调整，为临床应用开闢了新的途径，同时也提高了证据生成和安全性检验的标准。

技术创新、日益增长的监管压力和营运韧性的融合如何重塑竞争优势和临床应用格局？

由于探针化学的进步、日益严格的安全性和可重复性监管要求，以及对术中和照护现场成像解决方案需求的不断增长，光学成像剂领域正经历着一场变革。奈米颗粒工程和染料化学的创新提高了亮度、光稳定性和靶向特异性，从而实现了以前难以实现的新型成像模式和组合。同时，设备灵敏度和便携性的提升也为床边和手术应用创造了机会，在这些应用中，光学对比度可以直接指导临床决策。

评估近期美国关税措施对供应链、生产决策和临床时间表的更广泛的营运和策略影响

2025年美国关税的累积影响加剧了依赖进口原料、特殊试剂和精密製造组件的光学成像剂开发相关人员的成本和供应链复杂性。关税相关的成本增加给上游供应商带来压力，迫使製造商重新评估其供应商网络，评估近岸外包机会，并根据其合约结构和竞争地位自行承担或转嫁成本。这些事态发展凸显了供应链透明度和长期筹资策略的重要性。

详细的细分揭示了由模态主导的设计选择、特定应用的证据要求以及最终用户的采购行为，这些因素共同塑造了商业化策略。

详细的产品细分有助于明确产品和应用优先级，突显创新和投资能够带来最大临床和商业性回报的领域。产品类型包括造影剂、萤光染料、发光探针和分子探针。造影剂进一步细分为金奈米颗粒、微气泡和量子点，而萤光染料则细分为 Alexa Fluor 探针、花菁染料和靛氰绿。这些区分至关重要，因为每种分类在亮度、光稳定性、生物相容性和监管复杂性方面各有优劣。基于成像模式的分类使相关人员能够开发和部署涵盖生物发光成像、萤光成像、光学同调断层扫描和光声成像的解决方案，而特定成像模式的要求决定了探针的结构、激发和发射参数以及仪器相容性。

区域间在市场接受度、监管复杂性和供应链影响方面的差异，需要製定量身定制的市场进入和商业化策略。

区域趋势对监管预期、支付方环境以及对市场准入和扩大策略至关重要的实施路径产生了不同的影响。在美洲，临床研究人员和医疗保健系统优先考虑快速的术中和即时检测应用，因此对能够缩短手术时间并提高诊断准确性的工具有着强劲的需求。该地区还拥有复杂的报销环境以及广泛的公共和私人研究资金筹措管道。在欧洲、中东和非洲，必须解决不同的法规结构和医疗保健系统能力缺口问题，这需要製定量身定制的监管策略和弹性价格设定模式，以适应不同的采购惯例实践。

策略联盟、製造能力和科技差异化如何决定竞争定位和收购吸引力

光学影像剂领域的竞争格局由三者组成：专业创新者、不断拓展产品线的成熟生命科学公司，以及将利基技术实用化的大学衍生企业。主要企业正致力于将先进的探针化学技术与临床检验项目和可扩展的生产能力相结合，以加快产品进入临床应用的速度并提升其价值提案。同时，Start-Ups的新创公司往往凭藉其敏捷性和创新性科学脱颖而出，尤其是在靶向奈米颗粒和新一代萤光染料化学等领域。在这些领域，先发优势能够带来长期的临床差异化。

在复杂的商业环境中，采取切实可行的策略行动，以确保供应弹性、临床检验和可扩展的商业化。

产业领导者应采取一系列切实可行的措施，将创新转化为持续的市场优势和临床影响。首先，早期研发阶段应与明确的临床适应症和相关人员的需求保持一致，确保探针化学成分和模式选择能够直接对应目标手术中的可衡量结果。这种一致性可以减少后续监管方面的阻力，并加快与支付方的沟通。其次，应加强供应商多元化和合约保护，以降低进口关税和原材料短缺带来的风险。此外，应尽可能投资于关键部件的冗余采购和本地化生产，以确保临床试验按时完成。

调查方法概述：为确保研究结果的可靠性，我们说明阐述了初步访谈、文献综述、法规审查和多方面检验。

本研究结合了专家面对面访谈、近期同行评审文献综述以及监管指南和公开文件的分析，旨在全面了解光学成像剂的现状。面对面访谈对象包括化学家、临床研究人员、法规事务专业人员和采购负责人，以收集从研发到应用整个生命週期的观点。文献综述重点关注探针化学、成像设备和临床试验方法的最新进展，以确保技术准确性并与当前实践相符。

整合技术可行性、证据需求和营运重点，最终确定决定实用化和推广成功与否的因素。

总而言之，光学影像剂在提高诊断准确性、指导治疗性介入以及在临床诊疗指南提供可操作的见解方面具有巨大的潜力，但要充分发挥这一潜力，需要化学、临床证据、监管策略和运营执行等方面的协调配合。奈米颗粒、染料化学和多模态方法的创新拓展了技术能力，但监管机构和支付方的期望也日益提高，要求能够证明患者获益并保证可靠的生产。供应链中断和关税波动带来了新的营运风险，必须透过采购多元化和策略性投资来增强韧性，从而积极应对这些风险。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的光学显影剂市场

  • 造影
    • 金奈米粒子
    • 微气泡
    • 量子点
  • 萤光染料
    • Alexa Florprobe
    • 花菁染料
    • 靛氰绿
  • 发光探针
  • 分子探针

9. 依影像方式分類的光学成像剂市场

  • 生物发光成像
  • 萤光影像
  • 光学同调断层扫描
  • 光声成像

第十章 按应用分類的光学成像剂市场

  • 心血管影像
  • 消化影像
  • 神经影像学
  • 肿瘤影像
    • 乳癌影像学
    • 肺癌影像
    • 前列腺癌影像学

第十一章 以最终用户分類的光学成像剂市场

  • 生技公司
  • 诊断中心
  • 医院
  • 製药公司
  • 研究所

第十二章 光学成像剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 光学造影剂市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国光学成像剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国光学造影剂市场

第十六章：中国光学造影剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Bruker Corporation
  • Canon Inc.
  • Carl Zeiss Meditec AG
  • FUJIFILM Holdings Corporation
  • Hamamatsu Photonics KK
  • Heidelberg Engineering
  • Hologic Inc.
  • Koninklijke Philips NV
  • Leica Microsystems
  • Nikon Corporation
  • Olympus Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Topcon Corporation
Product Code: MRR-AE420CB152FB

The Optical Imaging Agent Market was valued at USD 2.45 billion in 2025 and is projected to grow to USD 2.57 billion in 2026, with a CAGR of 6.66%, reaching USD 3.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.45 billion
Estimated Year [2026] USD 2.57 billion
Forecast Year [2032] USD 3.85 billion
CAGR (%) 6.66%

Comprehensive introduction to optical imaging agents emphasizing technological integration, clinical translation pressures, and strategic development imperatives

The field of optical imaging agents sits at the intersection of cutting-edge chemistry, molecular biology, and clinical diagnostics, and it now commands attention from clinicians, researchers, and commercial stakeholders seeking higher-contrast, more specific, and safer imaging solutions. Advances in probe design, imaging instrumentation, and multimodal integration have expanded the clinical utility of optical tools beyond research labs into intraoperative guidance, targeted diagnostics, and noninvasive disease monitoring. Alongside these technical improvements, regulatory pathways and reimbursement frameworks have begun to adapt, creating new routes for clinical adoption while raising the bar for evidence generation and safety validation.

As technical feasibility converges with clinical need, industry participants face a landscape of accelerated innovation and heightened scrutiny. Developers must demonstrate not only the unique performance attributes of contrast agents, fluorescent dyes, luminescent probes, and molecular probes, but also reproducible manufacturing, robust quality control, and clear clinical value propositions tied to patient outcomes. Investors and strategic partners are increasingly focused on end-to-end solutions that integrate reagent chemistry, imaging hardware, and data analytics to deliver actionable results at the point of care. Consequently, early-stage collaboration among chemists, imaging specialists, regulatory experts, and clinicians has become essential to de-risk translation and speed clinical acceptance.

Looking ahead, the introduction of novel nanoparticle formulations and targeted molecular constructs offers promise for improved selectivity and reduced off-target effects, while ongoing work to standardize imaging protocols and performance metrics will support broader adoption. In this context, stakeholders should prioritize clear clinical indications, streamlined regulatory strategies, and manufacturing scalability to ensure that technical innovation translates into meaningful clinical and commercial outcomes.

How converging technological advances, regulatory rigor, and operational resilience are reshaping competitive advantage and clinical adoption dynamics

The landscape for optical imaging agents is undergoing transformative shifts driven by several converging forces: advances in probe chemistry, tighter regulatory emphasis on safety and reproducibility, and increasing demand for intraoperative and point-of-care imaging solutions. Innovations in nanoparticle engineering and dye chemistry have improved brightness, photostability, and target specificity, enabling new imaging modalities and combinations that were previously impractical. At the same time, instrumentation has become more sensitive and portable, creating opportunities for bedside and surgical applications where optical contrast can directly inform clinical decisions.

Simultaneously, regulators and health technology assessors are insisting on higher evidentiary standards, requiring developers to produce robust clinical performance data, harmonized imaging protocols, and clearer demonstrations of patient benefit. This regulatory tightening has pushed companies to invest earlier in clinical validation and to design trials that capture meaningful endpoints. Moreover, payer scrutiny is prompting clearer articulation of cost-effectiveness and value-based use cases, which favors integrated solutions that reduce downstream costs or improve procedural outcomes.

Finally, supply chain resilience and manufacturing quality have become strategic differentiators. As demand for complex formulations grows, organizations that can demonstrate reliable GMP manufacturing, effective scale-up plans, and secure raw material sourcing will command greater trust among clinical partners and procurement teams. Together, these shifts are redefining competitive advantage in the sector, privileging players who can align deep technical capability with clinical evidence generation and operational excellence.

Evaluating the broad operational and strategic consequences of recent US tariff measures on supply chains, manufacturing decisions, and clinical timelines

The cumulative impact of recent United States tariff actions in 2025 has amplified cost and supply-chain complexity for stakeholders dependent on imported raw materials, specialized reagents, and precision manufacturing components used in optical imaging agent development. Tariff-related cost increases have pressured upstream suppliers and compelled manufacturers to reassess supplier networks, evaluate nearshoring possibilities, and absorb or pass on costs depending on contractual structures and competitive positioning. These dynamics have highlighted the importance of supply-chain transparency and long-term sourcing strategies.

In addition to immediate cost implications, tariffs have influenced strategic timelines for product launches and clinical studies. Organizations facing higher input costs have frequently deferred noncritical investments, consolidated vendor relationships to secure volume discounts, or accelerated qualification of alternative suppliers to mitigate exposure. Some firms have explored relocating certain manufacturing steps or analytical testing to jurisdictions with more favorable trade conditions to preserve margin and reduce logistical uncertainty. These adaptations require investment in vendor qualification, regulatory filing updates, and quality oversight to ensure continuity of clinical-grade outputs.

Moreover, tariffs have sharpened conversations around resilience and value chain control among investors and corporate leaders. Firms that can demonstrate diversified sourcing, inventory buffers calibrated to clinical trial schedules, and contractual protections against abrupt cost shifts find themselves better positioned to maintain clinical development timelines. Going forward, tariff impacts will continue to influence where companies invest in manufacturing capacity, how they structure supplier agreements, and the degree to which they prioritize vertical integration versus strategic outsourcing.

In-depth segmentation reveals modality-driven design choices, application-specific evidence needs, and end-user procurement behaviors that dictate commercialization strategies

Deep segmentation clarifies product and application priorities and highlights where innovation and investment will have the highest clinical and commercial payoff. Based on Product Type, the field includes Contrast Agents, Fluorescent Dyes, Luminescent Probes, and Molecular Probes, with Contrast Agents further differentiated into Gold Nanoparticles, Microbubbles, and Quantum Dots and Fluorescent Dyes subdivided into Alexa Fluor Probes, Cyanine Dyes, and Indocyanine Green; these distinctions matter because each class offers different trade-offs in brightness, photostability, biocompatibility, and regulatory complexity. Based on Modality, stakeholders are developing and deploying solutions across Bioluminescence Imaging, Fluorescence Imaging, Optical Coherence Tomography, and Photoacoustic Imaging, and modality-specific requirements dictate probe architecture, excitation and emission parameters, and instrumentation compatibility.

Based on Application, use cases range across Cardiovascular Imaging, Gastrointestinal Imaging, Neurological Imaging, and Oncology Imaging, with Oncology Imaging further examined through Breast Cancer Imaging, Lung Cancer Imaging, and Prostate Cancer Imaging; each clinical domain imposes unique sensitivity, targeting, and safety expectations that influence clinical trial design and commercialization pathways. Based on End User, the principal adopters comprise Biotechnology Companies, Diagnostic Centers, Hospitals, Pharmaceutical Companies, and Research Institutes, and these end-user categories differ in procurement cycles, evidence thresholds, and integration needs. Taken together, this segmentation underscores that a one-size-fits-all approach will not succeed: product development must align chemistry and modality with the specific clinical application and the procurement behavior of targeted end users.

Regional differentiation across adoption, regulatory complexity, and supply-chain exposure demands tailored market entry and commercialization approaches

Regional dynamics shape regulatory expectations, payer environments, and adoption pathways in distinct ways that matter for market entry and scale-up strategies. In the Americas, clinical investigators and health systems emphasize rapid translation into intraoperative and point-of-care use cases, with strong demand for tools that reduce procedural time or improve diagnostic yield; this region also presents complex reimbursement landscapes and robust private and public research funding channels. In Europe, Middle East & Africa, stakeholders navigate diverse regulatory frameworks and heterogeneous health system capacities, which makes tailored regulatory strategies and flexible pricing models essential for adoption across countries with varied procurement practices.

In the Asia-Pacific region, rapid investment in healthcare infrastructure, growing clinical research capacity, and a rising number of centers adopting advanced imaging modalities create opportunities for scale, but these opportunities contend with local manufacturing priorities and variable regulatory timelines. Each region also displays different supply-chain risk profiles and tariff exposure, which influence decisions about where to site manufacturing, how to structure distributor relationships, and the extent to which localization will affect cost and access. Consequently, effective regional strategies combine local regulatory expertise, partnerships with established clinical centers, and adaptable commercialization models that reflect the operational realities of each geography.

How strategic partnerships, manufacturing readiness, and scientific differentiation determine competitive positioning and acquisition appeal

Competitive dynamics in the optical imaging agent space reflect a mix of specialist innovators, established life sciences firms expanding their portfolios, and academic spinouts translating niche technologies. Leading organizations invest in integrated capabilities that combine advanced probe chemistry with clinical validation programs and scalable manufacturing to shorten time-to-clinic and strengthen value propositions. At the same time, nimble startups often outperform on agility and novel science, particularly in areas such as targeted nanoparticles and next-generation fluorescent dye chemistries where first-mover scientific advantage can create long-term clinical differentiation.

Partnerships and strategic alliances play a central role in advancing complex programs, with many companies choosing to collaborate with instrument manufacturers, clinical research networks, and contract manufacturers to accelerate development and de-risk scale-up. Licensing deals and co-development arrangements enable diffusion of proprietary chemistries into broader platforms while preserving route-to-market benefits for originators. In parallel, contract research and manufacturing organizations that can meet stringent quality standards and support method transfer have become critical enablers of commercialization. Investors and acquirers are evaluating company portfolios through dual lenses of technical uniqueness and operational readiness, favoring entities that present clear clinical plans, validated analytical methods, and defensible IP.

Practical strategic actions for leaders to secure supply resilience, clinical validation, and scalable commercialization in a complex operating environment

Industry leaders should pursue a pragmatic set of actions to translate innovation into durable market advantage and clinical impact. First, align early-stage development with clear clinical indications and stakeholder needs so that probe chemistry and modality selection directly address measurable outcomes in targeted procedures. This alignment reduces downstream regulatory friction and accelerates payer conversations. Second, strengthen supplier diversification and contractual protections to reduce exposure to import tariffs and raw material shortages, and where feasible invest in redundant sourcing or localized manufacturing for critical components to safeguard clinical timelines.

Third, embed evidence-generation strategies into product roadmaps, prioritizing trials and real-world data collection that demonstrate patient outcomes, workflow efficiency, and economic value. Fourth, pursue collaborative pathways with instrumentation partners and clinical sites to co-develop end-to-end solutions that simplify adoption for hospitals and diagnostic centers. Fifth, maintain rigorous quality systems and early GMP planning to ensure that scale-up does not introduce regulatory setbacks. Finally, adopt flexible commercial models-such as bundled offerings, outcome-linked pricing, or service-enabled deployments-that respond to diverse end-user procurement preferences and support faster uptake. By executing these measures, leaders can convert technical promise into reproducible clinical benefit and sustainable commercial performance.

Methodological summary detailing primary interviews, literature synthesis, regulatory review, and multi-source triangulation to ensure robust findings

This research synthesizes primary interviews with domain experts, a review of recent peer-reviewed literature, and an analysis of regulatory guidance and public filings to develop a comprehensive view of the optical imaging agent landscape. Primary interviews included chemists, clinical investigators, regulatory affairs specialists, and procurement professionals to capture perspectives across the development and adoption lifecycle. The literature review emphasized recent advances in probe chemistry, imaging instrumentation, and clinical trial methodologies, ensuring technical accuracy and alignment with contemporary practice.

Analytical methods combined qualitative synthesis with cross-case comparison to identify recurrent themes in technology performance, clinical evidence generation, and operational readiness. Regulatory analysis focused on guidance documents, approval pathways for companion diagnostics and imaging agents, and emerging requirements for clinical validation. Supply-chain and tariff impact assessments relied on documented trade actions, reported vendor adjustments, and observed shifts in procurement strategies to produce an operationally grounded view of risk and adaptation. Throughout, methodological rigor included triangulation of multiple data sources and validation of key findings with subject-matter experts to ensure relevance and reliability.

Concluding synthesis of technological promise, evidence imperatives, and operational priorities that will determine successful translation and adoption

In conclusion, optical imaging agents present compelling opportunities to improve diagnostic precision, guide interventions, and deliver actionable insights at the point of care, but realizing that potential requires coordinated attention to chemistry, clinical evidence, regulatory strategy, and operational execution. Innovations in nanoparticles, dye chemistries, and multimodal approaches have expanded technical capabilities, while regulatory and payer expectations increasingly demand demonstrable patient benefit and reliable manufacturing. Supply-chain disruptions and tariff shifts have introduced new operational risks that must be actively managed through diversified sourcing and strategic investments in resilience.

Successful organizations will therefore integrate early clinical alignment with robust quality systems and adaptable commercial models. Strategic partnerships across instrumentation providers, clinical networks, and manufacturing specialists will accelerate adoption and de-risk scale-up. Meanwhile, regionally tailored approaches that reflect regulatory, reimbursement, and procurement realities will be essential for global impact. By prioritizing evidence generation, supply resiliency, and close collaboration with clinical end users, developers can translate scientific advances into meaningful clinical improvements and sustainable business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Optical Imaging Agent Market, by Product Type

  • 8.1. Contrast Agents
    • 8.1.1. Gold Nanoparticles
    • 8.1.2. Microbubbles
    • 8.1.3. Quantum Dots
  • 8.2. Fluorescent Dyes
    • 8.2.1. Alexa Fluor Probes
    • 8.2.2. Cyanine Dyes
    • 8.2.3. Indocyanine Green
  • 8.3. Luminescent Probes
  • 8.4. Molecular Probes

9. Optical Imaging Agent Market, by Modality

  • 9.1. Bioluminescence Imaging
  • 9.2. Fluorescence Imaging
  • 9.3. Optical Coherence Tomography
  • 9.4. Photoacoustic Imaging

10. Optical Imaging Agent Market, by Application

  • 10.1. Cardiovascular Imaging
  • 10.2. Gastrointestinal Imaging
  • 10.3. Neurological Imaging
  • 10.4. Oncology Imaging
    • 10.4.1. Breast Cancer Imaging
    • 10.4.2. Lung Cancer Imaging
    • 10.4.3. Prostate Cancer Imaging

11. Optical Imaging Agent Market, by End User

  • 11.1. Biotechnology Companies
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
  • 11.4. Pharmaceutical Companies
  • 11.5. Research Institutes

12. Optical Imaging Agent Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Optical Imaging Agent Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Optical Imaging Agent Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Optical Imaging Agent Market

16. China Optical Imaging Agent Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Bruker Corporation
  • 17.7. Canon Inc.
  • 17.8. Carl Zeiss Meditec AG
  • 17.9. FUJIFILM Holdings Corporation
  • 17.10. Hamamatsu Photonics K.K.
  • 17.11. Heidelberg Engineering
  • 17.12. Hologic Inc.
  • 17.13. Koninklijke Philips N.V.
  • 17.14. Leica Microsystems
  • 17.15. Nikon Corporation
  • 17.16. Olympus Corporation
  • 17.17. PerkinElmer, Inc.
  • 17.18. Siemens Healthineers
  • 17.19. Topcon Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPTICAL IMAGING AGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OPTICAL IMAGING AGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MICROBUBBLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MICROBUBBLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MICROBUBBLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY QUANTUM DOTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY QUANTUM DOTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY QUANTUM DOTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ALEXA FLUOR PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ALEXA FLUOR PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ALEXA FLUOR PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CYANINE DYES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CYANINE DYES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CYANINE DYES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY INDOCYANINE GREEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY INDOCYANINE GREEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY INDOCYANINE GREEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUMINESCENT PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUMINESCENT PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUMINESCENT PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MOLECULAR PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MOLECULAR PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MOLECULAR PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHOTOACOUSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHOTOACOUSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHOTOACOUSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY NEUROLOGICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY NEUROLOGICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY NEUROLOGICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BREAST CANCER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BREAST CANCER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BREAST CANCER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUNG CANCER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUNG CANCER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUNG CANCER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PROSTATE CANCER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PROSTATE CANCER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PROSTATE CANCER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 165. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 189. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 197. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 200. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)